Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Synucleinopathies: clinical and pathological implications.

J E Galvin1, V M Lee, J Q Trojanowski

  • 1Alzheimer's Disease Research Center, Department of Neurology, Campus Box 8111, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA. galvinj@neuro.wustl.edu

Archives of Neurology
|February 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.

The journal of prevention of Alzheimer's disease·2024
Same author

Editorial: How Will Aducanumab Approval Impact AD Research?

The journal of prevention of Alzheimer's disease·2021
Same author

Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions.

Acta neuropathologica communications·2021
Same author

Pathological drivers of neurodegeneration in suspected non-Alzheimer's disease pathophysiology.

Alzheimer's research & therapy·2021
Same author

Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease.

Neuropathology and applied neurobiology·2020
Same author

Editorial: Screening for Mild Cognitive Impairment: There Is the Will but Is There a Way?

The journal of prevention of Alzheimer's disease·2020

Synucleinopathies, like Parkinson disease, involve alpha-synuclein protein aggregates. Understanding the symmetry between familial and sporadic forms may unlock new diagnostic and therapeutic strategies for these neurodegenerative disorders.

Area of Science:

  • Neuroscience
  • Pathology
  • Genetics

Background:

  • Synucleinopathies are neurodegenerative disorders characterized by alpha-synuclein protein aggregates in neurons and glia.
  • Abnormal filamentous aggregates of alpha-synuclein are linked to disease progression and neuronal degeneration.
  • Familial and sporadic Parkinson disease share common alpha-synuclein lesions, presenting an 'enigmatic symmetry'.

Purpose of the Study:

  • To investigate the underlying mechanisms of synucleinopathies.
  • To clarify the 'enigmatic symmetry' observed in Parkinson disease pathogenesis.
  • To identify novel diagnostic and therapeutic targets for synucleinopathies.

Main Methods:

  • Review of existing literature on synucleinopathies and Parkinson disease.

Related Experiment Videos

  • Analysis of genetic and pathological data related to alpha-synuclein.
  • Comparative study of familial and sporadic forms of Parkinson disease.

    • Main Results:

    • The study highlights the central role of alpha-synuclein aggregation in synucleinopathies.
    • It emphasizes the shared pathological hallmarks between familial (mutated alpha-synuclein) and sporadic (wild-type alpha-synuclein) Parkinson disease.
    • The 'enigmatic symmetry' suggests common pathways despite different initiating factors.

    Conclusions:

    • Clarifying the symmetry in synucleinopathies is crucial for understanding neurodegeneration.
    • This understanding is expected to drive the development of new diagnostic tools and treatments.
    • Targeting alpha-synuclein pathways offers potential therapeutic avenues for a range of disorders.